- Home
- RGNX vs EBS Comparison
RGNX vs EBS Comparison
Compare RGNX & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGNX
- EBS
- Stock Information
- Founded
- RGNX 2008
- EBS 1998
- Country
- RGNX United States
- EBS United States
- Employees
- RGNX N/A
- EBS N/A
- Industry
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- RGNX Health Care
- EBS Health Care
- Exchange
- RGNX Nasdaq
- EBS Nasdaq
- Market Cap
- RGNX 451.1M
- EBS 423.6M
- IPO Year
- RGNX 2015
- EBS 2006
- Fundamental
- Price
- RGNX $12.50
- EBS $9.92
- Analyst Decision
- RGNX Strong Buy
- EBS Strong Buy
- Analyst Count
- RGNX 8
- EBS 2
- Target Price
- RGNX $28.50
- EBS $13.50
- AVG Volume (30 Days)
- RGNX 525.7K
- EBS 974.6K
- Earning Date
- RGNX 11-05-2025
- EBS 11-05-2025
- Dividend Yield
- RGNX N/A
- EBS N/A
- EPS Growth
- RGNX N/A
- EBS N/A
- EPS
- RGNX N/A
- EBS 2.53
- Revenue
- RGNX $155,782,000.00
- EBS $851,600,000.00
- Revenue This Year
- RGNX $203.79
- EBS N/A
- Revenue Next Year
- RGNX $0.72
- EBS $19.24
- P/E Ratio
- RGNX N/A
- EBS $3.91
- Revenue Growth
- RGNX 74.95
- EBS N/A
- 52 Week Low
- RGNX $5.04
- EBS $4.02
- 52 Week High
- RGNX $12.28
- EBS $12.73
- Technical
- Relative Strength Index (RSI)
- RGNX 76.74
- EBS 72.12
- Support Level
- RGNX $10.24
- EBS $8.85
- Resistance Level
- RGNX $11.00
- EBS $10.08
- Average True Range (ATR)
- RGNX 0.63
- EBS 0.45
- MACD
- RGNX 0.28
- EBS 0.13
- Stochastic Oscillator
- RGNX 93.57
- EBS 88.75
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.